PD Integrin Signaling Therapy Companies

Integrin Signaling-Targeted Parkinson's Disease Therapy Companies

Overview

Integrin Signaling-Targeted Parkinson's Disease Therapy Companies

Overview

Integrin signaling represents a promising but emerging therapeutic target for Parkinson's disease (PD). While no companies have advanced integrin-specific therapies into clinical trials for PD specifically, several companies have programs targeting related pathways including focal adhesion kinase (FAK), integrin-linked kinase (ILK), and cell adhesion mechanisms that intersect with neurodegenerative processes. This page catalogs companies working on integrin-related approaches and relevant research.

<div class="infobox">
<div class="infobox-header">Integrin Pathway PD Therapy Landscape</div>
<div class="infobox-content">
<table>
<tr><th>Direct Integrin Agonists</th><td>Research only</td></tr>
<tr><th>FAK Modulators</th><td>Preclinical</td></tr>
<tr><th>ILK Inhibitors</th><td>Research only</td></tr>
<tr><th>Cell Adhesion Therapies</th><td>Preclinical</td></tr>
</table>
</div>
</div>

Related Pharmaceutical Companies

Several major pharmaceutical companies with PD programs work on pathways that intersect with integrin signaling, particularly LRRK2 (leucine-rich repeat kinase 2) which regulates integrin-dependent signaling [1].

Denali Therapeutics

Headquarters: South San Francisco, California, USA Ticker: NASDAQ: DNLI Focus: Biopharmaceuticals for neurodegenerative diseases

Denali Therapeutics is leading the development of LRRK2 inhibitors for Parkinson's disease. While not targeting integrins directly, LRRK2 signaling intersects with integrin pathways through multiple mechanisms:

• LRRK2 regulates integrin-mediated cell adhesion and cytoskeletal dynamics
• DNL151 (BIIB122): LRRK2 inhibitor in Phase 1b, partnered with Biogen
• DNL343: LRRK2 inhibitor program in Phase 1

Pipeline:

| Drug | Mechanism | Phase | Status |
|------|-----------|-------|--------|
| DNL151 (BIIB122) | LRRK2 inhibitor | Phase 1b | Completed |
| DNL343 | LRRK2 inhibitor | Phase 1 | Active |

Biogen

Headquarters: Cambridge, Massachusetts, USA Ticker: NASDAQ: BIIB Focus: Neurodegenerative disease therapies

Biogen has an active Parkinson's disease pipeline through its partnership with Denali Therapeutics on LRRK2 inhibitors:

• BIIB122 (DNL151): LRRK2 inhibitor option from Denali
• The company's expertise in α-synuclein biology complements integrin pathway research

Roche

Headquarters: Basel, Switzerland Ticker: SIX: RO Focus: Neuroscience

Roche has an active neuroscience division with PD programs:

• R5055: α-synuclein antibody in Phase 1
• Internal research on cell adhesion molecules and neuroprotection

Preclinical and Research Companies

Research Tool and Platform Companies

Several companies provide research tools and platform technologies relevant to integrin drug discovery:

| Company | Technology | Relevance |
|---------|-----------|-----------|
| ChemieTek | Small molecule libraries | FAK inhibitor screening compounds |
| MedChemExpress | Research chemicals | Integrin ligand mimetics |
| Tocris/Bio-Techne | Biological reagents | Integrin research tools |
| R&D Systems | Proteins | Integrin subunit research |

Academic Spinoffs

The integrin-PD field remains primarily academic, with most advances coming from research institutions:

• University of Copenhagen: Integrin-FAK signaling in dopaminergic neurons
• University of Pennsylvania: Microglial integrin research
• Stanford University: α-synuclein-integrin interactions

Clinical Precedents from Other Diseases

Integrin-targeting drugs are approved for other conditions, demonstrating clinical viability [3](https://pubmed.ncbi.nlm.nih.gov/32990156/):

| Drug | Target | Indication | Company | Status |
|------|--------|-----------|--------|--------|
| Natalizumab | α4 integrin | Multiple sclerosis | Biogen/Elan | Approved |
| Abciximab | αIIbβ3 | Anti-platelet | Eli Lilly | Approved |
| Vedolizumab | α4β7 | IBD | Takeda | Approved |
| Lifitegrast | LFA-1 | Dry eye | Novartis | Approved |

These precedents demonstrate that integrin modulation is clinically feasible. Repurposing or analog development for CNS indications remains an opportunity.

Therapeutic Approaches in Development

FAK Modulation

Focal adhesion kinase (FAK) is a central mediator of integrin signaling. FAK modulators in development include:

• Preclinical FAK inhibitors: Originally developed for cancer, showing neuroprotective potential in dopaminergic neurons [4](https://pubmed.ncbi.nlm.nih.gov/33574892/)
• Selectivity challenges: Cancer-directed FAK inhibitors may be too broad for chronic CNS use

Integrin Agonists

Rather thanBlocking integrins, activating integrins may support neuronal survival:

• Fibronectin fragments: Support neuronal process outgrowth
• Laminin-mimetic peptides: Promote neurite outgrowth
• Agonist antibodies: Activate α5β1 signaling

Anti-inflammatory Integrin Targeting

Microglial integrins drive neuroinflammation in PD. Targeting these may reduce pathology [5](https://doi.org/10.1002/glia.23945):

• αMβ2 (Mac-1) antagonists: Reduce microglial activation
• αvβ3 antagonists: Block pro-inflammatory signaling
• Selectivity requirements: Must not disrupt beneficial integrin function

Companies with Relevant Platforms

Several companies have platforms that could be applied to integrin-PD therapies:

Recursion Pharmaceuticals

Focus: Phenotypic screening and computational biology

Recursion uses phenotypic screening to identify therapeutic candidates across multiple disease areas including neurodegeneration. Their approach could identify integrin modulators through unbiased phenotypic screening.

Recursion's Approach:

• High-content imaging of disease phenotypes
• Computational biology platform
• Potential for integrin pathway screening

Vincere Biosciences

Focus: Neurodegeneration

Vincere Biosciences focuses on molecular targets in neurodegeneration with an emphasis on protein homeostasis and cell stress pathways. Integrin-dependent cell adhesion may be relevant to their platform.

Manifold Bio

Focus: Protein engineering

Manifold Bio's protein engineering capabilities could be applied to developing integrin-targeting therapeutic antibodies or engineered proteins.

Research and Funding Landscape

Active Research Areas

Funding Sources

• Michael J. Fox Foundation: LRRK2 and related pathway research
• NIH/NINDS: Neurodegeneration biology
• Foundations: Parkinson's UK, Parkinson's Foundation

Market Opportunity

Unmet Need

• No disease-modifying PD therapies exist
• Current treatments address symptoms only
• Integrin pathways offer neuroprotective approach

Challenges

• BBB penetration: Integrin modulators must cross blood-brain barrier
• Selectivity: Broad integrin inhibition causes side effects
• Chronic dosing: Safety margin required for long-term treatment

Cross-References

Related Mechanism Pages

• [Integrin Signaling in Parkinson's Disease](/mechanisms/integrin-signaling-parkinsons)
• [FAK Signaling in Neurodegeneration](/mechanisms/fak-signaling)
• [LRRK2 Pathway](/mechanisms/lrrk2-pathway)

Related Company Pages

• [PD Pipeline](/companies/pd-pipeline)
• [Denali Therapeutics](/companies/denali-therapeutics)
• [Biogen](/companies/biogen)

Related Disease Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [PD Neuroinflammation](/mechanisms/neuroinflammation-pathway)

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov/) - Clinical trial database
• [Michael J. Fox Foundation](https://www.michaeljfox.org/) - PD research funding
• [Parkinson's Foundation](https://www.parkinson.org/) - Patient resources

References

Pathway Diagram

The following diagram shows the key molecular relationships involving PD Integrin Signaling Therapy Companies discovered through SciDEX knowledge graph analysis: